logo
logo

InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M

Feb 09, 2021•over 4 years ago

Round Type

series b

Utrecht

Description

InteRNA Technologies announced today the closing of an extended Series B financing round amounting to EUR 18.5M in total. This Series B round was led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round. The funding will enable the clinical evaluation of the Company’s microRNA lead candidate, INT-1B3, in patients with advanced solid tumors

Company Information

Company

Int 1 B3

Location

Utrecht, Utrecht, Netherlands

About

AurorA Science (www.aurorascience.eu) is a biotech investment company integrating an innovative financial and industrial approach in the research and development challenge. The company is focused on independent and entrepreneurial biotech start-ups in Europe with high therapeutic potential, providing industrial and financial support.